Zach Klaassen
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Zach Klaassen
Jun 30, 2024, 14:00 |
Blog
UroToday.com - Exploring imaging options and impact to treatment strategies in nmCPRC
UroToday.com shared on X: "Navigating the Nuances: Exploring imaging options and impact to treatment strategies in…
Jun 24, 2024, 01:48 |
Insight
Novel PARP inhibitor saruparib in metastatic hormone-sensitive prostate cancer
UroToday shared a post on X: . "The EvoPAR-Prostate 01 Trial:…
Jun 6, 2024, 04:56 |
Societies
Zach Klaassen: Biomarker analyses in aRCC from Ph 3 CLEAR trial by Toni Choueiri
Zach Klaassen, Urology Oncologist at Georgia Cancer Center, shared a post on X: "Biomarker analyses…
May 8, 2024, 07:32 |
Insight
Zach Klaassen: Survey on using intravesical chemo for BCG unresponsive NMIBC
Zach Klaassen, Urology Oncologist at Georgia Cancer Center, shared on X: . "Survey on clinical…
All:
4
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube